Patents by Inventor Tadashi Kadowaki

Tadashi Kadowaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210295157
    Abstract: By an information process device, a data decomposition method, or a data decomposition program stored in a computer-readable non-transitory storage medium, model data including multiple values is approximated by approximate data including a combination of basis data and coefficient data. A basis data candidate that constitutes the approximate data is selected. An approximate data candidate and an evaluation metric that evaluates the approximate data candidate are calculated. A regression model representing a relationship between the evaluation metric and the basis data candidate is generated. The selection, calculation, and generation are executed at least once. The coefficient data is calculated. The basis data candidate is selected to cause the regression model to more accurately predict the evaluation metric.
    Type: Application
    Filed: March 16, 2021
    Publication date: September 23, 2021
    Inventors: TADASHI KADOWAKI, MITSURU AMBAI
  • Publication number: 20210124988
    Abstract: An apparatus has a first function of selecting, from individual prediction models, candidate models, a second function of training the candidate models using a training dataset, a third function of applying a test dataset to a candidate integrated model to calculate an evaluation metric, and a fourth function of generating a regression expression between the evaluation metric and the candidate combination. A controller repeats a sequence of the first to fourth functions while the first function selects new individual models for each sequence until a termination condition is satisfied. The regression expression generated with an additional value of the evaluation metric from the new candidate combination for each sequence has a higher prediction accuracy on average as the number of the repeated sequences increases. A determiner determines an integrated model based on the candidate integrated models and values of the evaluation metric after the termination condition is satisfied.
    Type: Application
    Filed: October 27, 2020
    Publication date: April 29, 2021
    Inventor: Tadashi KADOWAKI
  • Publication number: 20200199689
    Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
    Type: Application
    Filed: March 4, 2020
    Publication date: June 25, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
  • Patent number: 10517861
    Abstract: Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: December 31, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Pallavi Sachdev
  • Publication number: 20180209980
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 26, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
  • Publication number: 20180136216
    Abstract: Biomarkers are provided that predict whether a human subject having a renal cell carcinoma is in need of a combination therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate) and everolimus. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a renal cell carcinoma.
    Type: Application
    Filed: May 27, 2016
    Publication date: May 17, 2018
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki
  • Patent number: 9945862
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: April 17, 2018
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
  • Publication number: 20170191137
    Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
    Type: Application
    Filed: March 16, 2017
    Publication date: July 6, 2017
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
  • Publication number: 20160089366
    Abstract: Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.
    Type: Application
    Filed: May 12, 2014
    Publication date: March 31, 2016
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Pallavi Sachdev
  • Publication number: 20140187577
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
    Type: Application
    Filed: May 31, 2012
    Publication date: July 3, 2014
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
  • Publication number: 20140148483
    Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
    Type: Application
    Filed: May 16, 2012
    Publication date: May 29, 2014
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
  • Publication number: 20100086931
    Abstract: An object of the present invention is to provide a method, a probe, a primer, an antibody, a reagent, and a kit for assaying an action of a pladienolide derivative to a living subject. According to the present invention, there is provided a method for assaying an action of the pladienolide derivative using a decrease in gene expression level as an index.
    Type: Application
    Filed: March 5, 2008
    Publication date: April 8, 2010
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yoshiharu Mizui, Naoko Hata, Masao Iwata, Rie Sugano, Naoki Toritsuka, Taku Yoshida, Mai Uesugi, Tadashi Kadowaki
  • Publication number: 20100021918
    Abstract: An object of the present invention is to provide a method, a probe, a primer, an antibody, a reagent, and a kit for assaying an action of a pladienolide derivative to a living subject. According to the present invention, there is provided a method for assaying an action of the pladienolide derivative using splicing defect as an index.
    Type: Application
    Filed: March 5, 2008
    Publication date: January 28, 2010
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yoshiharu Mizui, Naoko Hata, Masao Iwata, Koji Sagane, Mai Uesugi, Tadashi Kadowaki, Taku Yoshida
  • Patent number: 7259418
    Abstract: A semiconductor device comprises varactor regions Va and transistor regions Tr. An active region for a varactor is formed with a substrate contact impurity diffusion region obtained by doping an N well region with N-type impurity at a relatively high concentration. However, any extension region (or LDD region) as in a varactor of a known semiconductor device is not formed in the active region for a varactor. On the other hand, parts of a P well region located to both sides of the polysilicon gate electrode in the transistor region Tr are formed with high-concentration source/drain regions and extension regions. Therefore, the extendable range of a depletion layer is kept wide to extend the capacitance variable range of the varactor.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: August 21, 2007
    Assignee: Matsushita Electric Industrial Co., Ltd.
    Inventors: Tadashi Kadowaki, Hiroyuki Umimoto, Takato Handa
  • Patent number: 7034407
    Abstract: A substrate 11 consists of a semiconductor layer 12 as an element formation region and an STI 13 as an isolation region. A gate dielectric 15 is provided on the semiconductor layer 12, and a gate electrode 14 is provided to extend from the top of the gate dielectric 15 to the top of the STI 13. A sidewall 30 for covering the sides of the gate electrode 14 is provided to extend across the top of the semiconductor layer 12 to the tops of regions of the STI 13 adjacent to the outer edges of the semiconductor layer 12. The sidewall 30 is employed as an ion implantation mask for forming high-concentration impurity diffusion layers 16 each serving as a source/drain region.
    Type: Grant
    Filed: June 24, 2003
    Date of Patent: April 25, 2006
    Assignee: Matsushita Electric Industrial Co., Ltd.
    Inventors: Masahiro Imade, Tadashi Kadowaki, Hiroyuki Umimoto
  • Publication number: 20050087818
    Abstract: A substrate 11 consists of a semiconductor layer 12 as an element formation region and an STI 13 as an isolation region. A gate dielectric 15 is provided on the semiconductor layer 12, and a gate electrode 14 is provided to extend from the top of the gate dielectric 15 to the top of the STI 13. A sidewall 30 for covering the sides of the gate electrode 14 is provided to extend across the top of the semiconductor layer 12 to the tops of regions of the STI 13 adjacent to the outer edges of the semiconductor layer 12. The sidewall 30 is employed as an ion implantation mask for forming high-concentration impurity diffusion layers 16 each serving as a source/drain region.
    Type: Application
    Filed: June 24, 2003
    Publication date: April 28, 2005
    Inventors: Masahiro Imade, Tadashi Kadowaki, Hiroyuki Umimoto
  • Publication number: 20050045888
    Abstract: A semiconductor device comprises varactor regions Va and transistor regions Tr. An active region for a varactor is formed with a substrate contact impurity diffusion region obtained by doping an N well region with N-type impurity at a relatively high concentration. However, any extension region (or LDD region) as in a varactor of a known semiconductor device is not formed in the active region for a varactor. On the other hand, parts of a P well region located to both sides of the polysilicon gate electrode in the transistor region Tr are formed with high-concentration source/drain regions and extension regions. Therefore, the extendable range of a depletion layer is kept wide to extend the capacitance variable range of the varactor.
    Type: Application
    Filed: July 23, 2004
    Publication date: March 3, 2005
    Inventors: Tadashi Kadowaki, Hiroyuki Umimoto, Takato Handa